1,916 material Form 8-K filings that 1,609 companies we cover made with the SEC in July 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Neurogene agreed on June 30, 2026 to sell 3,500,000 common shares at $30.00 each, with pre-funded warrants for up to 666,666 more shares offered in place of common stock for some investors. Underwriters exercised in full their option to buy 624,999 additional shares on July 1, 2026, and the company expects net proceeds of about $134.8 million. The company says these proceeds, plus existing cash, will fund operations into the first quarter of 2029, but the sale adds new shares outstanding for existing shareholders.
3,500,000 common shares offered at $30.00 per share, plus pre-funded warrants for up to 666,666 shares
Underwriters exercised in full their option for up to 624,999 additional shares on July 1, 2026
Expected net proceeds of approximately $134.8 million after underwriting discounts and estimated expenses
Offering expected to close July 2, 2026; company expects cash to last into the first quarter of 2029
Whirlpool announced on July 1, 2026 that it will close its Supsa manufacturing facility in Apodaca, Mexico, by the second quarter of 2027, moving production to its Ramos Arizpe, Mexico plant and across its supply chain. The company estimates $165 million in total restructuring costs, with about $70 million expected to be cash expenditures, so shareholders face a large charge now while the filing does not quantify the expected savings.
Supsa facility in Apodaca, Mexico to close by the second quarter of 2027, with production shifted to Ramos Arizpe, Mexico
Estimated total restructuring costs of $165 million: up to $95 million asset impairment, $30 million employee-related, and $40 million other
About $100 million of the $165 million expected in 2026; about $70 million total cash expenditures, with $15 million expected in 2026
Actions expected to be substantially complete in 2027
Compass Therapeutics furnished an updated corporate presentation dated July 2026 that includes data from its COMPANION-002 study of tovecimig plus paclitaxel in biliary tract cancer. The study met its primary endpoint of overall response rate (18.0% vs 5.3%) and showed a longer median progression-free survival (4.7 vs 2.6 months), but overall survival was not significantly different (8.9 vs 9.4 months) because of crossover.
Primary endpoint overall response rate was 18.0% for tovecimig plus paclitaxel vs 5.3% for paclitaxel alone (p=0.0228)
Median progression-free survival was 4.7 vs 2.6 months (HR=0.44, p<0.0001); median overall survival was 8.9 vs 9.4 months (HR=1.05, p=0.78)
Company plans an FDA meeting in Q3 2026 and a BLA filing in Q4 2026, with potential approval in 2027
Company reported $195 million in cash and marketable securities at Q1 2026, with runway into 2028
Aon's board approved an additional $7.5 billion share repurchase authorization on June 26, 2026, on top of about $0.8 billion remaining under the existing program as of March 31, 2026. At the same meeting, shareholders did not approve the advisory vote on executive compensation, while all 13 director nominees were elected.
Board approved an additional $7.5 billion repurchase authorization on June 26, 2026; the program does not obligate Aon to buy any particular amount of shares.
Existing program had about $0.8 billion of remaining authorization as of March 31, 2026.
Advisory say-on-pay vote failed: 69,888,299 for, 110,798,636 against, 1,112,848 abstain.
All 13 director nominees were elected at the June 26, 2026 Annual Meeting, including Lester B. Knight and Gregory C. Case.
Culp reported fourth-quarter fiscal 2026 net sales of $51.6 million, up 5.8% from a year earlier, but its net loss widened slightly to $2.2 million, or $0.18 per diluted share, from $2.1 million, or $0.17 per share. For the full year ended May 3, 2026, sales fell 4.6% to $203.5 million while the net loss narrowed to $10.2 million, or $0.81 per share, from $19.1 million. The company expects to recover about $7.0 million in IEEPA tariff refunds in the first quarter of fiscal 2027, which it says should reduce net debt to about $5.0 million at that quarter-end.
Q4 net sales $51.6 million, up 5.8% from $48.8 million a year earlier; gross profit fell to $6.8 million from $7.7 million
Q4 net loss $2.2 million, or $0.18 per diluted share, versus $2.1 million, or $0.17, in the prior-year quarter
Full-year net loss $10.2 million, or $0.81 per share, versus $19.1 million, or $1.53, in fiscal 2025
Outlook: about $7.0 million in IEEPA tariff refunds expected in Q1 fiscal 2027; net debt expected near $5.0 million at quarter-end
UniFirst reported fiscal third-quarter 2026 results for the quarter ended May 30, 2026. Revenue rose 3.9% to $634.4 million, but net income fell to $19.9 million from $39.7 million, and diluted EPS was $1.09 versus $2.13, after about $20.7 million of costs tied to the pending Cintas merger. The company no longer provides financial guidance because of that pending transaction.
Revenue rose 3.9% to $634.4 million from $610.8 million a year earlier.
Net income was $19.9 million versus $39.7 million; diluted EPS was $1.09 versus $2.13.
About $20.7 million of Cintas merger-related transaction costs were included in the quarter's results.
The FTC issued a Second Request on June 11, 2026, and the transaction is expected to close in the second half of calendar 2026.
On June 30, 2026, FMC agreed to sell 30,319,166 shares of common stock to Tessenderlo Group NV at $13.30 per share, for an aggregate purchase price of $403,244,907.80, subject to customary conditions including regulatory approvals. After closing, Tessenderlo is expected to own about 20.0% of FMC's outstanding shares, up from less than 1.0% today, and FMC intends to use the proceeds to pay down debt toward its approximately $1 billion target.
30,319,166 shares sold at $13.30 each, for an aggregate $403,244,907.80, with closing subject to regulatory approvals
Tessenderlo expected to hold about 20.0% of outstanding shares after closing, versus less than 1.0% now
Investor agreement gives Tessenderlo one board seat while it holds at least 10.0%, and a 36-month lock-up on transfers
Proceeds go to debt paydown toward an approximately $1 billion target; FMC says this concludes its strategic options review announced in February 2026
FactSet reported results for its fiscal third quarter ended May 31, 2026, with revenue up 6.4% to $622.9 million while GAAP diluted EPS fell 9.6% to $3.50. Adjusted diluted EPS rose 6.1% to $4.53, but GAAP results absorbed restructuring, severance and CEO compensation costs. The company reaffirmed its fiscal 2026 outlook, so shareholders get a mixed quarter with no change to guidance.
Revenue was $622.9 million, up 6.4% from $585.5 million a year earlier; organic revenue rose 7.0%.
GAAP diluted EPS was $3.50 versus $3.87; adjusted diluted EPS was $4.53 versus $4.27.
Restructuring/severance charges of $19.6 million weighed on operating income; GAAP operating margin was 26.7% versus 33.2%.
Fiscal 2026 guidance was reaffirmed, including GAAP revenues of $2,450 million to $2,470 million and GAAP diluted EPS of $14.85 to $15.35.
General Mills reported a fourth-quarter net loss of $2.0 billion, or $3.74 per diluted share, driven by $1.8 billion in non-cash goodwill and brand intangible charges and a $1.0 billion valuation loss tied to the planned Brazil divestiture. Adjusted diluted EPS rose to $0.95 in the quarter, while full-year net sales fell 5% to $18.4 billion and the company guided fiscal 2027 adjusted diluted EPS to $3.00 to $3.20, which would be lower than fiscal 2026's $3.55.
Q4 net sales rose 1% to $4.6 billion; organic net sales were flat
Q4 diluted loss per share was $3.74 versus EPS of $0.53 a year earlier; adjusted diluted EPS was $0.95
Full-year diluted loss per share was $0.16 versus EPS of $4.10; adjusted diluted EPS was $3.55, down 16% in constant currency
Fiscal 2027 outlook: adjusted diluted EPS of $3.00 to $3.20 and adjusted operating profit down 13% to 8% in constant currency; quarterly dividend of $0.61 per share declared
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.